TH-MYCN tumors, but not tumor-derived cell lines, are adrenergic lineage, GD2+, and responsive to anti-GD2 antibody therapy.
Saved in:
| Title: | TH-MYCN tumors, but not tumor-derived cell lines, are adrenergic lineage, GD2+, and responsive to anti-GD2 antibody therapy. |
|---|---|
| Authors: | McNerney, K. O.1, Karageorgos, S.2, Ferry, G. M.2, Wolpaw, A. J.1,3, Burudpakdee, C.2, Khurana, P.2, Toland, C. N.2, Vemu, R.1, Vu, A.1, Hogarty, M. D.1,4, Bassiri, H.2,4 bassiri@chop.edu |
| Source: | OncoImmunology. 2022, Vol. 11 Issue 1, p1-13. 13p. |
| Database: | Academic Search Ultimate |
| FullText | Links: – Type: pdflink Text: Availability: 0 |
|---|---|
| Header | DbId: asn DbLabel: Academic Search Ultimate An: 161372827 AccessLevel: 2 PubType: Academic Journal PubTypeId: academicJournal PreciseRelevancyScore: 0 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: TH-MYCN tumors, but not tumor-derived cell lines, are adrenergic lineage, GD2+, and responsive to anti-GD2 antibody therapy. – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AR" term="%22McNerney%2C+K%2E+O%2E%22">McNerney, K. O.</searchLink><relatesTo>1</relatesTo><br /><searchLink fieldCode="AR" term="%22Karageorgos%2C+S%2E%22">Karageorgos, S.</searchLink><relatesTo>2</relatesTo><br /><searchLink fieldCode="AR" term="%22Ferry%2C+G%2E+M%2E%22">Ferry, G. M.</searchLink><relatesTo>2</relatesTo><br /><searchLink fieldCode="AR" term="%22Wolpaw%2C+A%2E+J%2E%22">Wolpaw, A. J.</searchLink><relatesTo>1,3</relatesTo><br /><searchLink fieldCode="AR" term="%22Burudpakdee%2C+C%2E%22">Burudpakdee, C.</searchLink><relatesTo>2</relatesTo><br /><searchLink fieldCode="AR" term="%22Khurana%2C+P%2E%22">Khurana, P.</searchLink><relatesTo>2</relatesTo><br /><searchLink fieldCode="AR" term="%22Toland%2C+C%2E+N%2E%22">Toland, C. N.</searchLink><relatesTo>2</relatesTo><br /><searchLink fieldCode="AR" term="%22Vemu%2C+R%2E%22">Vemu, R.</searchLink><relatesTo>1</relatesTo><br /><searchLink fieldCode="AR" term="%22Vu%2C+A%2E%22">Vu, A.</searchLink><relatesTo>1</relatesTo><br /><searchLink fieldCode="AR" term="%22Hogarty%2C+M%2E+D%2E%22">Hogarty, M. D.</searchLink><relatesTo>1,4</relatesTo><br /><searchLink fieldCode="AR" term="%22Bassiri%2C+H%2E%22">Bassiri, H.</searchLink><relatesTo>2,4</relatesTo><i> bassiri@chop.edu</i> – Name: TitleSource Label: Source Group: Src Data: <searchLink fieldCode="JN" term="%22OncoImmunology%22">OncoImmunology</searchLink>. 2022, Vol. 11 Issue 1, p1-13. 13p. |
| PLink | https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=asn&AN=161372827 |
| RecordInfo | BibRecord: BibEntity: Identifiers: – Type: doi Value: 10.1080/2162402X.2022.2075204 Languages: – Code: eng Text: English PhysicalDescription: Pagination: PageCount: 13 StartPage: 1 Titles: – TitleFull: TH-MYCN tumors, but not tumor-derived cell lines, are adrenergic lineage, GD2+, and responsive to anti-GD2 antibody therapy. Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: McNerney, K. O. – PersonEntity: Name: NameFull: Karageorgos, S. – PersonEntity: Name: NameFull: Ferry, G. M. – PersonEntity: Name: NameFull: Wolpaw, A. J. – PersonEntity: Name: NameFull: Burudpakdee, C. – PersonEntity: Name: NameFull: Khurana, P. – PersonEntity: Name: NameFull: Toland, C. N. – PersonEntity: Name: NameFull: Vemu, R. – PersonEntity: Name: NameFull: Vu, A. – PersonEntity: Name: NameFull: Hogarty, M. D. – PersonEntity: Name: NameFull: Bassiri, H. IsPartOfRelationships: – BibEntity: Dates: – D: 01 M: 01 Text: 2022 Type: published Y: 2022 Identifiers: – Type: issn-print Value: 21624011 Numbering: – Type: volume Value: 11 – Type: issue Value: 1 Titles: – TitleFull: OncoImmunology Type: main |
| ResultId | 1 |
